Diebold Nixdorf, Incorporated (DBD) is a publicly traded Technology sector company. As of May 21, 2026, DBD trades at $71.48 with a market cap of $2.39B and a P/E ratio of 27.98. DBD moved +4.20% today. Year to date, DBD is +9.27%; over the trailing twelve months it is +46.33%. Its 52-week range spans $34.88 to $89.05. Analyst consensus is buy with an average price target of $100.00. Rallies surfaces DBD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes DBD SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $71.48 |
| Market Cap | $2.39B |
| P/E Ratio | 27.98 |
| EPS | $2.57 |
| Dividend Yield | 0.00% |
| 52-Week High | $89.05 |
| 52-Week Low | $34.88 |
| Volume | 4 |
| Avg Volume | 0 |
| Revenue (TTM) | $3.81B |
| Net Income | $97.50M |
| Gross Margin | 25.26% |
2 analysts cover DBD: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $100.00.